Additional file 3: Supplementary Table 1. Patient characteristics of the training cohort. Supplementary Table 2. Characteristics of the UTUC validation cohort. Supplementary Table 3. Characteristics o
Introduction: Tumor-informed minimal residual disease (MRD) monitoring assays based on plasma circulating tumor DNA (ctDNA) are increasingly integrated into the clinical management of patients with ca
Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics, yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the b
